Figure 5.

EGFR inhibition led to decreased Cbl-b-mediated degradation of MyD88 by attenuating Src activation. (A) CAL27 cells were pretreated with 100 μg/mL cetuximab, gefitinib, IgG or DMSO for 2 h and then stimulated with 1 μg/mL LPS for 24 h. Western blotting was performed using anti-p-Src and anti-MyD88 antibodies at 0, 3, and 6 h, respectively. Co-IP and western blotting showed the interaction of Cbl-b with MyD88 (B) and that of Src with Cbl-b and MyD88 (C). Data were represented as mean ± SD of at least three independent experiments; *P<0.05, **P<0.01; ***P<0.001.